
|Videos|May 3, 2016
Dr. Abou-Alfa on Emerging PD-L1 Agents in Liver Cancer
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses what is on the horizon for the use of PD-L1 agents in liver cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
4
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
5







































